Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX HFA versus ENTOCORT EC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX HFA versus ENTOCORT EC.
ASMANEX HFA vs ENTOCORT EC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
Budesonide is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to anti-inflammatory effects via inhibition of inflammatory mediators such as cytokines and prostaglandins.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
9 mg orally once daily in the morning for up to 8 weeks.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
Terminal elimination half-life is approximately 2-3 hours; clinically, the extended intestinal release formulation maintains local activity despite short systemic half-life.
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Primarily fecal (60-70%) with minimal renal excretion (<10%); extensively metabolized hepatically, metabolites excreted in bile and feces.
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid